Coherus Oncology (CHRS) Long-Term Debt Issuances (2016 - 2024)
Historic Long-Term Debt Issuances for Coherus Oncology (CHRS) over the last 6 years, with Q3 2024 value amounting to -$141000.0.
- Coherus Oncology's Long-Term Debt Issuances changed N/A to -$141000.0 in Q3 2024 from the same period last year, while for Dec 2024 it was $49.3 million, marking a year-over-year change of. This contributed to the annual value of $37.0 million for FY2024, which is N/A changed from last year.
- Per Coherus Oncology's latest filing, its Long-Term Debt Issuances stood at -$141000.0 for Q3 2024.
- In the past 5 years, Coherus Oncology's Long-Term Debt Issuances registered a high of $222.8 million during Q2 2020, and its lowest value of -$674000.0 during Q3 2020.
- Its 4-year average for Long-Term Debt Issuances is $114.1 million, with a median of $120.3 million in 2022.
- Over the last 5 years, Coherus Oncology's Long-Term Debt Issuances had its largest YoY gain of 12034864.86% in 2020, and its largest YoY loss of 53584.91% in 2020.
- Over the past 4 years, Coherus Oncology's Long-Term Debt Issuances (Quarter) stood at -$674000.0 in 2020, then soared by 33067.36% to $222.2 million in 2021, then tumbled by 77.73% to $49.5 million in 2022, then tumbled by 100.28% to -$141000.0 in 2024.
- Its Long-Term Debt Issuances was -$141000.0 in Q3 2024, compared to $49.5 million in Q3 2022 and $191.2 million in Q1 2022.